<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527798</url>
  </required_header>
  <id_info>
    <org_study_id>15-1978</org_study_id>
    <secondary_id>HHSN27500033</secondary_id>
    <secondary_id>HHSN27500035</secondary_id>
    <secondary_id>5R01FD005101-02</secondary_id>
    <nct_id>NCT02527798</nct_id>
  </id_info>
  <brief_title>Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)</brief_title>
  <official_title>Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will describe the safety of furosemide in premature infants at risk of
      bronchopulmonary dysplasia and determine the preliminary effectiveness and pharmacokinetics
      (PK) of furosemide. Funding Source - FDA OOPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants will receive a placebo or furosemide for 28 days. Blood samples will be collected for
      pharmacokinetic analysis.Premature infants will be randomized to receive placebo or
      furosemide in a dose escalating approach.

      Follow up information will be collected up to 7 days after the last dose and at 36 weeks post
      menstrual age. The final study assessment will occur at the time of discharge, early
      termination or transfer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as determined by adverse event experienced by participants. Description of safety of furosemide in premature infants at risk of BPD</measure>
    <time_frame>35 days for each participant</time_frame>
    <description>Safety will be assessed following initial study-specific procedure e.g., screening blood draws, dosing through 7 days post last study dose and it will be assessed by frequency and incidence of adverse events and serious adverse events. A safety monitoring committee (DMC) will be convened by NIH to review data and safety information from study participants throughout the study and prior to dose escalation into cohorts 2 and 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in moderate-severe BPD or death risk from baseline</measure>
    <time_frame>36 weeks postmenstrual age</time_frame>
    <description>Moderate-severe BPD or death risk will be defined by the NICHD Neonatal Research Network BPD outcome estimator. (https://neonatal.rti.org/index.cfm?fuseaction=BPDCalculator.start).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>6 Hr dosing: within 30 min, 2-4 hrs post dose, 12-18 hrs post last dose, within 30 min. prior to next dose. 24 hr dosing: within 30 min., 2-4 , 6-8, 12-16, 20-22 hrs post dose, 48-72 hrs post last dose and within 30 min before next dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>6 Hr dosing: within 30 min, 2-4 hrs post dose, 12-18 hrs post last dose, within 30 min. prior to next dose. 24 hr dosing: within 30 min., 2-4 , 6-8, 12-16, 20-22 hrs post dose, 48-72 hrs post last dose and within 30 min before next dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life</measure>
    <time_frame>6 Hr dosing: within 30 min, 2-4 hrs post dose, 12-18 hrs post last dose, within 30 min. prior to next dose. 24 hr dosing: within 30 min., 2-4 , 6-8, 12-16, 20-22 hrs post dose, 48-72 hrs post last dose and within 30 min before next dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of furosemide</measure>
    <time_frame>6 Hr dosing: within 30 min, 2-4 hrs post dose, 12-18 hrs post last dose, within 30 min. prior to next dose. 24 hr dosing: within 30 min., 2-4 , 6-8, 12-16, 20-22 hrs post dose, 48-72 hrs post last dose and within 30 min before next dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration Peak Plasma Concentration (Cmax) of furosemide</measure>
    <time_frame>6 Hr dosing: within 30 min, 2-4 hrs post dose, 12-18 hrs post last dose, within 30 min. prior to next dose. 24 hr dosing: within 30 min., 2-4 , 6-8, 12-16, 20-22 hrs post dose, 48-72 hrs post last dose and within 30 min before next dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Furosemide Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within cohort 1, infants will be randomized using a 3:1 scheme to receive furosemide or placebo. Those randomized to receive furosemide will receive (1mg/kg daily intravenously or 2 mg/kg daily enterally for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Furosemide Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 Infants will receive furosemide (1mg/kg every 6 hours intravenously or 2 mg/kg every 6 hours daily enterally) for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Furosemide Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 Infants will receive furosemide (2mg/kg every 6 hours intravenously or 4 mg/kg every 6 hours daily enterally) for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infants randomized to the placebo treatment group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide Cohort 1</intervention_name>
    <description>furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.</description>
    <arm_group_label>Furosemide Cohort 1</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide Cohort 2</intervention_name>
    <description>furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.</description>
    <arm_group_label>Furosemide Cohort 2</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide Cohort 3</intervention_name>
    <description>furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.</description>
    <arm_group_label>Furosemide Cohort 3</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar water will be administered in a equivalent volume as drug intervention.</description>
    <arm_group_label>Placebo Cohort 1</arm_group_label>
    <arm_group_label>Placebo Cohort 2</arm_group_label>
    <arm_group_label>Placebo Cohort 3</arm_group_label>
    <other_name>sugar water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Receiving positive airway pressure (nasal continuous airway pressure, nasal
             intermittent positive pressure ventilation, or nasal cannula flow &gt; 1LPM) or
             mechanical ventilation (high frequency or conventional)

          2. &lt; 29 weeks gestational age at birth

          3. 7-28 days postnatal age at time of first study dose

        Exclusion Criteria:

          1. Exposure to any diuretic ≤ 72 hours prior to first study dose

          2. Previous enrollment and dosing in current study, &quot;Safety of Furosemide in Premature
             Infants at Risk of Bronchopulmonary Dysplasia&quot;

          3. Hemodynamically significant patent ductus arteriosus, as determined by the
             investigator

          4. Major congenital anomaly (e.g. congenital diaphragmatic hernia, congenital pulmonary
             adenomatoid malformation)

          5. Meconium aspiration syndrome

          6. Known allergy to any diuretic

          7. Serum creatinine &gt;1.7 mg/dL &lt; 24 hours prior to first study dose

          8. BUN &gt;50 mg/dL &lt; 24 hours prior to first study dose

          9. Na &lt;125 mmol/L &lt; 24 hours prior to first study dose

         10. K ≤2.5 mmol/L &lt; 24 hours prior to first study dose

         11. Ca ≤ 6 mg/dL &lt; 24 hours prior to first study dose

         12. Indirect bilirubin &gt;10 mg/dL &lt; 24 hours prior to first study dose

         13. Any condition which would make the participant, in the opinion of the investigator,
             unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason E Lang, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew M. Laughon, MD, MPH</last_name>
    <phone>984-974-7851</phone>
    <email>matt_laughon@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leigh Gosnell, Project Lead</last_name>
    <phone>919-668-1280</phone>
    <email>leigh.gosnell@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital/University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sherry Courtney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aprille Febre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Florida Jacskonville Shands Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Hudak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wolfson Children's Hospital</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Hudak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John's Hopkins Al Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prabhu S Parimi, MD,MBA,CPE</last_name>
      <email>pparimi1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Miami Hospital</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Bombino, CCRP</last_name>
    </contact>
    <contact_backup>
      <email>susanabom@baptisthealth.net</email>
    </contact_backup>
    <investigator>
      <last_name>Jorge Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mina Hanna, MD</last_name>
      <email>mina.hanna@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Mina Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children at Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anijali Lyengar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather White</last_name>
      <phone>508-334-8315</phone>
      <email>heather.white@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence Rhein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-4225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheri Gauldin</last_name>
      <phone>816-234-3920</phone>
      <email>cagauldin@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Tamorah Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill/North Carolina Children's Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia R. Aliaga, MD, MPH</last_name>
      <phone>984-974-7846</phone>
      <email>sofia_aliaga@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Sofia R. Aliaga, MD, MHP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Hanover Regional Medical Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fernando Moya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital/The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Gutentag, BSN, RN</last_name>
      <phone>614-355-6626</phone>
      <email>julie.gutentag@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Slaughter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joseph El Khoury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

